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Inhibition of the Epidermal Growth Factor Receptor Suppresses
Telomerase Activity in HSC-1 Human Cutaneous Squamous Cell
Carcinoma Cells
Arief Budiyanto,Toshinori Bito, Makoto Kunisada, Masashi Ashida, Masamitsu Ichihashi, and Masato Ueda
Division of Dermatology, Clinical Molecular Medicine, Faculty of Medicine, Kobe University Graduate School of Medicine, Japan
Activation of telomerase, which stabilizes the telomere
length of chromosomes, is crucial for the continued
growth or progression of cancer cells. In a previous
study, we showed that telomerase is frequently activated
in skin tumors. Because epidermal growth factor plays
an important role during the tumorigenesis of epithelial
tissue, we have now examined the role of epidermal
growth factor signaling in regulating telomerase activ-
ity using HSC-1 human cutaneous squamous cell carci-
noma cells. Treatment of HSC-1 cells with AG 1478, an
inhibitor of the epidermal growth factor receptor, or
with a neutralizing antibody to the epidermal growth
factor receptor, signi¢cantly suppressed their telomer-
ase activity, in association with inhibiting their growth.
The suppression of telomerase activity was obvious at
day 3 and was maximal at day 5 after treatment with
AG 1478. The suppression of telomerase activity corre-
lated with the decreased expression of human telomer-
ase catalytic subunit (hTERT) mRNA, the rate-limiting
determinant of its enzyme activity. The expression of
c-Myc and of Sp1 proteins, transcription factors for
hTERT, were also suppressed byAG 1478 in HSC-1 cells,
but the expression of Ets-2 protein, another transcrip-
tion factor, was not a¡ected. The expression of Mad-1,
a competitor of c-Myc, was increased. Inhibition of
ERK, Src, or Akt suppressed telomerase activity in
HSC-1 cells, but to a lesser extent than did treatment
with AG 1478. Serum starvation suppressed telomerase
activity, but addition of epidermal growth factor or
transforming growth factor a did not increase it, indi-
cating the involvement of other epidermal growth fac-
tor receptor ligands in the activation of telomerase in
HSC-1 cells. These data indicate that blockade of the
epidermal growth factor receptor might be e¡ective in
inhibiting telomerase activity of squamous cell carcino-
mas, which would lead to the suppression of tumor
growth. Key words: Akt/ERK/human telomerase catalytic
subunit (hTERT)/Src. J Invest Dermatol 121:1088 ^1094, 2003
T
he immortalization of human cells is a critical step
during tumorigenesis. To immortalize human kerati-
nocytes, the loss of p16INK4A expression and the acti-
vation of telomerase are required (Kiyono et al, 1998).
Telomerase is a ribonucleoprotein enzyme (an RNA-
dependent DNA polymerase) that catalyzes the addition of
telomeric repeats (TTAGGG)n to telomeres, the distal ends of
eukaryotic chromosomes. Telomeres are essential elements that
protect chromosome ends from degradation and ligation. Telo-
merase is frequently activated in cancer cells, whereas its activity
is usually repressed in normal somatic cells except in some self-
renewing tissues with high regenerative potential, such as hema-
topoietic cells and epidermal keratinocytes (Harle-Bachor and
Boukamp, 1996). Telomerase activation is thus thought to be
crucial for the continued growth of cells by stabilizing telomere
length.
We previously reported that telomerase is frequently activated
in skin tumors. In addition, telomerase activation could be de-
tected in normal skin and showed a strong association with the
level of sun exposure, which suggests that telomerase activation
in the skin might be involved at an early stage of human photo-
carcinogenesis (Ueda et al, 1997).We also showed that telomerase
activity in skin tumors was strongly correlated with the expres-
sion of the human telomerase catalytic subunit (hTERT), as has
been shown in tumors of other organs (Wu A et al, 1999).
The promoter region of hTERT has been cloned (Horikawa
et al, 1999; Takakura et al, 1999) and the transcription factors
c-Myc and Sp1 have been shown to activate hTERT transcription
(Horikawa et al, 1999; Takakura et al, 1999;Wu K-J et al, 1999; Kyo
et al, 2000). Furthermore, Mad-1 has been shown to be a repressor
of hTERT gene expression by antagonizing c-Myc (Gˇnes et al,
2000; Oh et al, 2000). A recent study revealed that epidermal
growth factor (EGF) activates the hTERT promoter and that the
ETS motif located in the core promoter of hTERT is required for
the EGF-induced transactivation of hTERT (Maida et al, 2002).
Various reagents, including sex steroid hormones, growth fac-
tors, and retinoic acid, have been shown to upregulate or down-
regulate telomerase activity through various signaling pathways
(Kyo et al, 1999; Wang et al, 2000; Ding et al, 2002; Inui et al,
2002; Kyo and Inoue, 2002). Rea and Rice (2001) have shown that
EGF stimulates telomerase activity in a spontaneously immorta-
lized human epidermal cell line. EGF plays an important role in
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the development and progression of many solid tumors including
squamous cell carcinoma (SCC). Studies using EGF receptor
(EGFR) null mice have shown that the EGFR is required as an
essential survival signal for skin tumors (Sibilia et al, 2000). EGF
and EGFR are expressed in head and neck SCC and the level of
expression is associated with patient survival (Grandis et al, 1998),
and inhibition of SCC growth can be achieved by EGFR anti-
sense RNA or by monoclonal antibodies against the EGFR (He
et al, 1998; Herbst et al, 2001). We hypothesized that the EGFR
may play a role in regulating telomerase activity and we exam-
ined the e¡ect of inhibiting EGFR function on the telomerase
activity of HSC-1 human cutaneous SCC cells. A speci¢c inhibi-
tor of the EGFR inhibited telomerase activity in a dose-depen-
dent manner, and this was correlated with the decreased
expression of hTERT, c-Myc, and Sp1. ERK, Src, and Akt are
suggested to be involved in this signaling.
MATERIALS AND METHODS
Cell, cell culture, and reagents HSC-1 is an SCC cell line derived
from human skin (Kondo and Aso, 1981), and was a gift from Dr
Katagaka of the Yamagata University School of Medicine. The
immortalized human keratinocyte cell line HaCaT was kindly provided
by Dr Fusenig (Boukamp et al, 1988). Cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) (Life Technologies, Gaithersburg,
MD) supplemented with 10% fetal bovine serum (FBS). An EGFR
inhibitor (AG 1478), an MAPK ERK kinase inhibitor (PD 98059, termed
an ERK inhibitor here), an Src inhibitor (PP2), a PI3K/Akt inhibitor (LY
294002, termed an Akt inhibitor here), EGF, transforming growth factor a
(TGF-a), and a neutralizing antibody to EGFR were purchased from
Calbiochem (San Diego, CA). Each inhibitor and neutralizing antibody
was added after the cultured cells reached approximately 50%^60%
con£uency. Dimethylsulfoxide as a solvent at the concentration used in
this study (less than 0.2%) had no e¡ect on telomerase activity or other
analyses.
For studying the e¡ects of EGF and TGF-a on telomerase activity,
HSC-1 cells or HaCaT cells were incubated in low serum medium
(DMEM supplemented with 0.5% FBS) for 3 d. The cells were then
treated with 10 ng per ml EGF or TGF-a and extracted at day 2 along
with control cells incubated with normal serum medium (DMEM
supplemented with 10% FBS).
Proliferation assay Cell growth was determined by the MTS cell
proliferation assay (Promega, Madison, WI). Brie£y, HSC-1 cells were
cultured in 96-well plates and, 24 h after seeding, 0.25^2 mM AG 1478 was
added to the medium. Cells were incubated for the indicated times, and
then MTS reagent was added and allowed to react for 2 h. Absorbance at
490 nm was measured using a microplate reader (Emax; Molecular
Devices, Sunnyvale, CA).
Telomerase activity and hTERT expression Telomerase activity was
measured by the telomeric repeat ampli¢cation protocol (TRAP) using
the TRAPeze XL Telomerase Detection Kit from Intergen (Purchase,
NY) according to the manufacturer’s instructions. Brie£y, harvested cells
were resuspended in CHAPS XL lysis bu¡er and the lysates were
centrifuged at 12,000g for 20 min at 41C. The protein concentration of
each supernatant was measured by the Coomassie protein assay (Pierce,
Rockford, IL). Two microliters of each extract (0.35 mg per mL protein)
were added to the solution containing the TRAPeze XL reaction mix and
Taq polymerase (Takara, Shiga, Japan). The solution was subjected to 29
cycles of PCR (941C for 30 s, 591C for 30 s, and 721C for 1 min)
followed by a 551C extension step for 25 min. The PCR products were
electrophoresed on 10% nondenaturing polyacrylamide gels and were
stained with SYBR Green I nucleic acid gel stain (Molecular Probes,
Eugene, OR).
Expression of hTERTmRNAwas analyzed by RT-PCR ampli¢cation
as described previously, with slight modi¢cations (Wu A et al, 1999). Brie£y,
total RNA was isolated from the cells using ISOGEN (Nippon Gene,
Tokyo, Japan). cDNA was synthesized from 1 mg RNA using an RNA
PCR Kit Version 2.1 (Takara, Shiga, Japan) with random primers. PCR
primers used were as follows: (1) hTERT, LT5, 50 -CGGAAGAGT
GTCTGGAGCAA-30 (sense) and LT6, 50 -GGATGAAGCGGAGTCT
GGA-30 (antisense); (2) actin, actin1, 50 -GGGAATTCAAAACTGGAACG
GTGAAGG-30 (sense) and actin2, 50 -GGAAGCTTATCAAAGTCCTCGG
CCACA-30 (antisense). To amplify cDNA, 2.5 mL aliquots of reverse-
transcribed cDNA were subjected to PCR. The PCR conditions were as
follows: (1) hTERT, 36 cycles of denaturation at 941C for 30 s, annealing
at 601C for 30 s, and extension at 721C for 45 s; (2) actin, 25 cycles of
denaturation at 901C for 90 s, annealing at 601C for 90 s, and extension at
721C for 90 s. PCR products were electrophoresed in 2.5% NuSieve 3:1
agarose gels (Bioproducts, Rockland, ME). Quanti¢cation of TRAP assay
and hTERT mRNA was performed using NIH image analysis software
(version 1.62f). Brie£y, the image ¢les were opened in gray-scale mode by
NIH image. For density determination, a density slice of 100^250 was
selected and the ‘‘measure’’ command was used. Relative telomerase
activity was quanti¢ed by measuring the total density of telomerase
ladder bands and calculated as the ratio to the internal control. hTERT
expression was quanti¢ed by measuring the density of the RT-PCR band
and calculated as the ratio to actin.
Western blot analysis Western blotting was performed by the method
described previously (Kyo et al, 2000). Brie£y, 30 mg of protein were
electrophoresed on 10% sodium dodecyl sulfate polyacrylamide gels and
were transferred to polyvinylidene di£uoride membranes. Membranes
were incubated with speci¢c antibodies against c-Myc (N-262; Santa
Cruz, Santa Cruz, CA), Sp1 (1C6; Santa Cruz), Ets-2 (C-20; Santa Cruz),
Mad-1 (C-19; Santa Cruz), phosphorylated ERK1/2 (Tyr202/Tyr204; Cell
Signaling Technology, Beverly, CA), phosphorylated Src (Tyr527; Cell
Signaling Technology), phosphorylated Akt (Ser473; Cell Signaling
Technology), p16INK4a (H-156; Santa Cruz), or p21CIP1/WAF1 (187; Santa
Cruz), followed by reaction with horseradish peroxidase linked IgG.
Immunoreactive bands were visualized using the ImmunoStar reagents
(Wako, Osaka, Japan). After stripping, the membrane was reprobed with
polyclonal antiactin (Santa Cruz), anti-ERK1/2, anti-Src, and anti-Akt
(Cell Signaling Technology) antibodies that served as gel loading and
protein controls. Quanti¢cation of protein expression was done using
NIH image analysis software (version 1.62f).
Immunoprecipitation of EGFR phosphorylation EGFR antibody
(SC03, Santa Cruz) was incubated with protein G-Sepharose (Pharmacia,
Uppsala, Sweden) for 2 h at room temperature. Cell lysates (200 mg
protein) were then added and immunoprecipitated for 24 h at 41C. The
immuno-complexes were washed, electrophoresed, and analyzed by
immunoblotting using a phosphotyrosine antibody labeled with horsera-
dish peroxidase (PY20, Santa Cruz). Re-blotting of the membrane with the
EGFR antibody was performed to con¢rm the equal loading of EGFR.
RESULTS
An EGFR inhibitor, AG 1478, or an EGFR neutralizing anti-
body suppressed telomerase activity in HSC-1 cells Telomerase
activity was high in HSC-1 cells, as shown by the TRAP assay
(Fig 1a). In a time-course experiment, an EGFR inhibitor (AG
1478) slightly suppressed telomerase activity in HSC-1 cells at
days 1 and 2 after treatment and this suppressive e¡ect became
obvious at days 3 and 4, and then reached a maximum level at
day 5 (Fig 1a). The suppressive e¡ect on telomerase activity by
AG 1478 was concentration dependent. At a dose of 0.25 mM,
telomerase activity was not altered, whereas 1 mM AG 1478
induced an obvious suppression and maximum inhibition was
seen at a dose of 2 mM (Fig 1b). Blocking of EGFR by a
neutralizing antibody also suppressed the telomerase activity
similar to the level elicited byAG 1478 treatment (Fig 1c).
AG 1478 inhibited proliferation of HSC-1 cells To determine
whether the inhibition of telomerase activity by AG 1478 is
associated with the inhibition of cell growth, we measured cell
proliferation using the MTS assay. The growth of HSC-1 cells
was not altered within 2 d of treatment with 0.25^2 mM AG
1478, but a signi¢cant inhibition of cell growth of HSC-1 cells
was observed after 3 d of treatment with 1 or 2 mM AG 1478
(Fig 2).
AG 1478 suppressed expression of hTERT mRNA in HSC-1
cells To examine whether the suppression of telomerase activity
by AG 1478 is due to the reduced expression of hTERT, we
performed RT-PCR analysis. The expression of hTERTmRNA
started to decrease at day 1 after AG 1478 treatment (2 mM), and by
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day 3 the hTERT mRNA expression was almost completely
suppressed (Fig 3).
AG 1478 reduced expression of c-Myc and Sp1 but not of Ets-
2 in HSC-1 cells; AG 1478 slightly increased expression of
Mad-1 in these cells Previous studies have shown that Sp1
cooperates with c-Myc to activate hTERT transcription and
telomerase activity (Horikawa et al, 1999; Takakura et al, 1999;Wu
K-J et al, 1999; Kyo et al, 2000). In contrast, Mad-1 acts as a
suppressor for hTERT by antagonizing c-Myc (Gˇnes et al,
2000; Oh et al, 2000). To investigate whether the suppressive
e¡ect of AG 1478 on hTERT expression was mediated by a
modi¢cation of expression of c-Myc, Sp1, and/or Mad-1, we
performed western blot analysis. AG 1478 signi¢cantly reduced
the expression of c-Myc and Sp1 in HSC-1 cells (Fig 4). This
inhibition was observed at day 1 after AG 1478 treatment (2 mM)
and reached a maximum at days 4^5 for Sp1 and at days 3^5 for
c-Myc. On the other hand, AG 1478 treatment slightly increased
the level of Mad-1 protein expression. As the ETS motif is
required for EGF induction of hTERT expression (Maida et al,
2002), we also examined the expression of Ets-2 in HSC-1 cells.
The expression of Ets-2 was not altered by treatment with AG
1478, however (Fig 4).
AG 1478 did not alter the expression of p16INK4a or p21CIP1/WAF1
in HSC-1 cells To test whether the cyclin-dependent kinase
inhibitors p16INK4a or p21CIP1/WAF1 are involved in the suppre-
ssive e¡ect on telomerase or in the inhibitory e¡ect on cell
growth of HSC-1 cells elicited by AG 1478, their expression was
examined. AG 1478 (2 mM) did not alter the expression of
p16INK4a or p21CIP1/WAF1 (Fig 5).
Inhibitors for ERK, Src, orAkt suppressed telomerase activity
in HSC-1 cells To reveal the signal transduction pathway that
is involved in the inhibition of hTERTexpression byAG 1478, we
treated HSC-1 cells with inhibitors of signaling molecules that
are known to function downstream of the EGFR. First, we
examined the e¡ects of the inhibitors on the phosphorylation
status of their target molecules. Immunoprecipitation analysis
con¢rmed that 2 mM AG 1478 suppressed phosphorylation of the
EGFR in HSC-1 cells (Fig 6a). Furthermore, AG 1478 suppressed
the phosphorylation of ERK1/2, Src, and Akt in HSC-1 cells
(Fig 6a). An ERK inhibitor, PD 98059, at a dose of 50 mM
suppressed the phosphorylation of ERK1/2 but not of Src or of
Akt. An Src inhibitor, PP2, at a dose of 20 mM, suppressed the
phosphorylation of Src but not of ERK1/2 or of Akt. Finally, an
Akt inhibitor, LY 294002, at a dose of 20 mM, suppressed the
phosphorylation of Akt but not of ERK1/2 or of Src (Fig 6b).
Next, we investigated the e¡ects of these inhibitors on hTERT
mRNA expression by RT-PCR analysis. Fifty micromoles of
PD 98059 or 20 mM PP2 suppressed hTERTmRNA expression
but 20 mM LY 294002 did not alter it (Fig 6c). Telomerase
Figure1. The EGFR speci¢c inhibitor (AG 1478) or an EGFR neu-
tralizing antibody suppressed telomerase activity in HSC-1 cells. (a)
HSC-1 cells were treated with 2 mM AG 1478 and were extracted at di¡er-
ent times along with control solvent-treated cells. Lanes 1, 3, 5, 7, and 9,
controls at days 1^5, respectively; lanes 2, 4, 6, 8, and 10, AG 1478 treatment
at days 1^5, respectively. (b) HSC-1 cells were treated with 0.25, 1, or 2 mM
AG 1478 and were extracted at day 5 along with control solvent-treated
cells. (c) HSC-1 cells were treated with 2 mM AG 1478 or with 10 mg per
ml EGFR neutralizing antibody and were extracted at day 5 along with
control solvent-treated cells. The TRAP assay was performed to measure
telomerase activity. IC, internal control.
Figure 2. AG 1478 inhibited cell proliferation of HCS-1 cells. HSC-1
cells were treated with 0.25, 1, or 2 mM AG 1478 and were incubated for the
indicated times. The MTS assay was performed to measure cell prolifera-
tion. Control cells were treated with solvent.
Figure 3. AG 1478 suppressed expression of hTERT mRNA in
HSC-1 cells. HSC-1 cells were incubated with 2 mM AG 1478. Treated
cells were then extracted for RNA at di¡erent times along with control
solvent-treated cells and RT-PCR assays were performed using LT5/LT6
primers for the expression of hTERTmRNA. An actin mRNAwas used
as an internal control. Lanes 1, 3, 5, 7, and 9, solvent treatment at days 1^5,
respectively; lanes 2, 4, 6, 8, and 10, AG 1478 treatment at days 1^5, respec-
tively. Bottom panel: Relative levels of hTERTmRNA normalized to actin
as determined by densitometry using NIH image analysis software.
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activity of HSC-1 cells after treatment with these inhibitors was
also measured. The ERK inhibitor reduced the telomerase
activity (Fig 6d). Similar results were also observed when HSC-
1 cells were treated with an Src inhibitor or with an Akt
inhibitor. The extent of the suppressive e¡ects on telomerase by
each of these inhibitors alone was less than that elicited by AG
1478, however. Combinations of the inhibitors (PD 98059 þ
PP2 or PD 98059 þ LY 294002) suppressed telomerase to a
similar extent to AG 1478 (Fig 6d).
EGF and TGF-a, ligands for the EGFR, induced telomerase
activity in serum-starved HaCaT cells but not in serum-
starved HSC-1 cells HSC-1 cells cultured in low serum
medium (0.5% FBS) showed a suppression of telomerase activity
to about 50% the level found in cells cultured in normal serum
medium (10% FBS). Addition of EGF or TGF-a did not increase
telomerase activity in HSC-1 cells (Fig 7a). In contrast, HaCaT
cells cultured in low serum medium showed a decrease of
telomerase activity to about 30% that of the control and the
addition of EGF or TGF-a could restore it (Fig 7b).
DISCUSSION
Our results indicate that signaling from the EGFR is important
for the activation of telomerase in HSC-1 cells. The suppression
of telomerase correlated with the decrease of hTERTmRNA ex-
pression, which was presumably due to the suppressed expression
of c-Myc and Sp1.The decrease of hTERT, Sp1, and c-Myc at ear-
lier time points than telomerase is consistent with the fact that
telomerase is a very stable complex with a half-life of more than
24 h. The increased expression of the c-Myc antagonist Mad-1
could also have a suppressive e¡ect on hTERT transcription. On
the other hand, the expression of Ets-2 was not altered after
treatment of HSC-1 cells with AG 1478. This is consistent with a
previous study that showed that levels of Ets expression were not
altered by treatment with EGF (Maida et al, 2002). Modi¢cations
of the Ets protein, such as phosphorylation, will be necessary to
investigate the contribution of Ets to responses elicited by AG
1478.
AG 1478 inhibited the proliferation of HSC-1 cells. There are
several studies on the link between telomerase activity and cell
proliferation (Holt et al, 1996; Zhu et al, 1996; Maida et al, 2002).
One study showed that telomerase activity was repressed when
cells were growth arrested in either a quiescent state or a di¡er-
entiated state (Holt et al, 1996), whereas another study showed that
quiescent and dividing cells have similar levels of telomerase ac-
tivity (Zhu et al, 1996). One recent study showed that EGF
activated telomerase in NIH3T3 cells that overexpressed the
Figure 4. AG1478 reduced expression of
c-Myc and of Sp1 but not of Ets-2 and
slightly increased the expression of Mad-1
in HSC-1 cells. HSC-1 cells were incubated
with 2 mM AG 1478. Treated cells were then ex-
tracted at di¡erent times along with control sol-
vent-treated cells and western blot analysis of
cell lysates was performed to detect the expres-
sion of c-Myc, Sp1, Ets-2, and Mad-1 proteins.
The actin protein was used as an internal control
for normalization of protein loading. Lanes 1, 3,
5, 7, and 9, control solvent-treated cells at days 1^
5, respectively; lanes 2, 4, 6, 8, and 10, AG 1478
treatment at days 1^5, respectively. Bottom panel:
relative levels of Sp1, c-Myc, Ets-2, and Mad-1
normalized to actin as determined by densito-
metry using NIH image analysis software.
Figure 5. AG 1478 did not alter the expression of p16INK4a or p21CIP1/
WAF1 in HSC-1 cells. HSC-1 cells were incubated with 2 mMAG1478 and
were extracted at di¡erent times along with control solvent-treated cells.
Western blot analysis of cell lysates was performed to detect the expression
of p16INK4a and p21CIP1/WAF1 proteins. The actin protein was used as an in-
ternal control for normalization of protein loading. Lane 1, solvent treat-
ment; lanes 2, 3, and 4, AG 1478 treatment at days 3, 4, and 5, respectively.
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EGFR and in A-431 cells (Maida et al, 2002). EGF stimulated the
growth of NIH3T3 cells, however, but inhibited the growth of
A-431 cells, suggesting that there was no direct relationship be-
tween telomerase activity and cell proliferation (Maida et al,
2002). It is thus of interest to know whether growth suppression
was caused directly by the inhibited telomerase activity in HSC-1
cells. This will require further study using methods to inhibit tel-
omerase speci¢cally, such as an antisense oligonucleotide to
hTERT.
The roles of signaling molecules activated by the EGFR, in-
cluding ERK, Src, and Akt, on the telomerase activity of HSC-
1 cells were examined using speci¢c inhibitors. Inhibitors of
ERK, Src, or Akt inhibited telomerase activity, but to a lesser
extent than did the EGFR inhibitor. Combinations of inhibitors
(ERK inhibitor þ Src inhibitor or ERK inhibitor þ Akt inhi-
bitor) suppressed telomerase activity to a level similar to the sup-
pression elicited by the EGFR inhibitor, suggesting that the
simultaneous activation of several downstream signaling compo-
nents of the EGFR is involved in the full activation of telomerase
in HSC-1 cells. Consistent with this notion, AG 1478 was able to
inhibit the phosphorylation of ERK, Src, and Akt.
A previous study showed that the induction of telomerase eli-
cited by progesterone could be suppressed by an ERK inhibitor,
indicating the crucial role of ERK signaling for this e¡ect (Wang
et al, 2000). The hypoxia-induced increase in telomerase in A2780
and in HT-29 cells could also be repressed by an ERK inhibitor
(Seimiya et al, 1999). Furthermore, the upregulation of telomerase
in regenerating hepatocytes after partial hepatectomy was
repressed by an ERK inhibitor but not by a p38 MAPK inhibitor
(Inui et al, 2002). Regarding Src, it has been known to be acti-
vated by EGF (Osherov and Levitzki, 1994; Xian et al, 1997) and
Src activation has been shown to be crucial for tumor promotion
during skin carcinogenesis (Xian et al, 1997). Our ¢nding that an
Src inhibitor reduced telomerase activity in HSC-1 cells contra-
dicts a previous study that showed that chicken neuroretina cells
transfected with v-src did not have increased activity of telomer-
ase (Falchetti et al, 1999). This discrepancy might be due to di¡er-
ences in the types of cells studied. Our results showed that an
ERK or an Src inhibitor suppressed hTERT mRNA expression
in HSC-1 cells. In contrast, we found that an Akt inhibitor sup-
pressed telomerase activity but not hTERT mRNA expression.
This is consistent with previous studies, which revealed that Akt
increased telomerase activity not through transcription of
the hTERT gene, but through phosphorylation of the hTERT
Figure 6. Inhibitors for ERK, Src, or Akt suppressed telomerase
activity in HSC-1 cells. (a) Immunoprecipitation using the EGFR anti-
body, following western blotting with a phosphotyrosine antibody or an
EGFR antibody, demonstrated that AG 1478 suppressed the phosphoryla-
tion of EGFR.Western blots using phospho-ERK1/2 (p-ERK), phospho-
Src (p-Src), and phospho-Akt (p-Akt) showed that AG 1478 also suppressed
the phosphorylation of ERK1/2, Src, and Akt. (b) Western blots using
phospho-ERK1/2 (p-ERK), phospho-Src (p-Src), and phospho-Akt
(p-Akt) antibodies show the speci¢city of the ERK inhibitor (PD 98059),
the Src inhibitor (PP2), and the PI3K/Akt inhibitor (LY 294002), respec-
tively. (c) RT-PCR analysis shows the e¡ects of those inhibitors on hTERT
mRNA expression in HSC-1 cells. HSC-1 cells were treated with the in-
hibitors, and the treated cells were then extracted for RNA at di¡erent
times along with control solvent-treated cells and RT-PCR assays were
performed using LT5/LT6 primers for the expression of hTERT mRNA.
An actin mRNA was used as an internal control. Lane 1, control; lane 2,
AG 1478; lane 3, ERK inhibitor; lane 4, Akt inhibitor; lane 5, Src inhibitor.
(d) TRAP assays show the e¡ect of the inhibitors on telomerase activity in
HSC-1 cells. HSC-1 cells were treated with the inhibitors as noted. Treated
cells were then extracted at day 5 along with control solvent-treated cells
andTRAP assays were performed to measure telomerase activity. Lanes 1^7,
control solvent-treated cells, 2 mM AG 1478, ERK inhibitor, Src inhibitor,
ERK þ Src inhibitor, Akt inhibitor, and ERK þ Akt inhibitor, respec-
tively. IC, internal control.
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protein. Furthermore, an Akt inhibitor was shown to downregu-
late both hTERTpeptide phosphorylation and telomerase activity
(Kang et al, 1999; Akiyama et al, 2002). Taken together, the inhibi-
tion of telomerase activity in HSC-1 cells elicited byAG 1478 was
due to the accumulating e¡ects of inhibiting ERK, Src, and Akt,
but the inhibition of hTERTmRNA expression in these cells by
AG 1478 was possibly due to the inhibition of ERK and Src.
The introduction of p21CIP1/WAF1 into cells, including keratino-
cytes, inhibits telomerase activity (Kallassy et al, 1998; Harada et al,
2000;Wang et al, 2000). The introduction of p16INK4a into glioma
cells also inhibits telomerase (Fuxe et al, 2000), and inactivation of
p16INK4a is crucial for the immortalization of keratinocytes
(Kiyono et al, 1998).We examined whether the suppression of tel-
omerase byAG 1478 is accompanied by an increase of p21CIP1/WAF1
and/or p16INK4a protein but we found no signi¢cant increases,
which indicates that these proteins are not involved in the inhibi-
tory e¡ect of AG 1478 on telomerase activity in HSC-1 cells.
Our results showed that serum starvation in the culture med-
ium suppressed telomerase activity to about 50% the level in
control HSC-1 cells. Addition of EGF or TGF-a to the medium
did not increase telomerase activity, suggesting that other ligands
of the EGFR, such as heparin-binding EGF-like growth factor,
amphiregulin, and/or epiregulin, might be involved in activating
the EGFR in these cells (Hashimoto, 2000). In contrast, premalig-
nant HaCaT keratinocytes showed a decrease of telomerase activ-
ity (about 30% of the control) by serum starvation. Furthermore,
EGF or TGF-a restored the activity, indicating that signaling
through the EGFR is also important for activating telomerase in
HaCaT cells and that EGF and TGF-a can function as ligands for
the EGFR in these cells. Less of a reduction in telomerase activity
by low serum levels in HSC-1 cells compared with HaCaT cells
might indicate the presence of a constitutive mechanism for acti-
vation of the EGFR in HSC-1 cells. A mutant EGFR, such as
EGFRvIII (Lorimer and Lavictoire, 2001), that has constitutive
tyrosine kinase activity, was detected in glioblastoma cells. In
HSC-1 cells, the molecular weight of the EGFR detected by im-
munoprecipitation was that of normal EGF (175 kDa), not of
EGFRvIII (two bands of 150 and 140 kDa), which rules out the
possibility that these cells have EGFRvIII. The di¡erent degree of
telomerase suppression by the low serum level may also re£ect
the di¡erent malignant potentials of HSC-1 cells (fully malig-
nant) and HaCaT cells (premalignant). The reversible telomerase
activation in HSC-1 cells and in HaCaT cells cultured in low ser-
um may provide a suitable experimental model to detect growth
factors and/or environmental factors that regulate telomerase and
might allow their molecular mechanisms to be unveiled.We con-
clude that drugs that block EGFR signaling will show antitumor
e¡ects for cutaneous SCC by decreasing telomerase activity.
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